Compare Amgen, Inc. (AMGN) vs Micron Technology, Inc. (MU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Micron Technology, Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Micron Technology, Inc. trades at $926.79 (market cap $1.11T). The key difference: Micron Technology, Inc. is far larger — about 5.7× Amgen, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MU | |
|---|---|---|
Market Cap | $196.12B | $1.11T |
Sector | Health | Technology |
52-Week High | $388.16 | $1.21K |
52-Week Low | $271.18 | $104.88 |
Enterprise Value | $241.41B | $1.09T |
Dividend Yield | 2.77% | 0.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Micron Technology (MU) trades at $979.30, down 1.24% on the day, with strong technical support near $974 and bullish moving average signals. The company demonstrates exceptional fundamental strength with Q1 2026 EPS of $25.11 beating expectations by 20%, robust 55.91% net income margins, and accelerating revenue growth from $37.38B in 2025 to projected $90.3B in 2026. Recent news highlights the company's $250 billion AI memory investment and leadership in the semiconductor shortage cycle.
Outlook remains positive with 81% analyst buy ratings and $1,540 consensus price target representing 57% upside. Key opportunities include AI memory demand and humanoid robotics growth, while risks involve cyclical semiconductor exposure and competitive pressure from SK Hynix's Nasdaq debut. The stock presents a compelling growth story with strong earnings momentum and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
